Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

469 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients.
Assaf I, Bregni G, Anthoine G, Aparicio T, Artru P, Abdelghani MB, Buyse M, Chibaudel B, Coart E, Diaz M, Evrard C, Geboes K, Ghiringhelli F, Puleo F, Raimbourg J, Vandamme T, Van den Eynde M, Hendlisz A, Sclafani F. Assaf I, et al. Among authors: buyse m. Clin Colorectal Cancer. 2024 Sep 3:S1533-0028(24)00081-1. doi: 10.1016/j.clcc.2024.08.004. Online ahead of print. Clin Colorectal Cancer. 2024. PMID: 39341700
Benefit of Avasopasem Manganese on Severe Oral Mucositis in Head and Neck Cancer in the ROMAN Trial: Unplanned Secondary Analysis.
Anderson C, Salvaggio S, De Backer M, Chiem JC, Walker G, Saunders D, Lee CM, Dunlap N, Kennedy E, Beardsley R, Schoen B, Buyse M. Anderson C, et al. Among authors: buyse m. Adv Radiat Oncol. 2024 Nov 9;10(1):101674. doi: 10.1016/j.adro.2024.101674. eCollection 2025 Jan. Adv Radiat Oncol. 2024. PMID: 39678920 Free PMC article.
The tyranny of non-inferiority trials.
Tannock IF, Buyse M, De Backer M, Earl H, Goldstein DA, Ratain MJ, Saltz LB, Sonke GS, Strohbehn GW. Tannock IF, et al. Among authors: buyse m. Lancet Oncol. 2024 Oct;25(10):e520-e525. doi: 10.1016/S1470-2045(24)00218-3. Lancet Oncol. 2024. PMID: 39362263 Review.
End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?
Degtyarev E, Bolaños N, Brody JD, Buchbinder A, Buyse M, Fuchs M, Halabi S, Hemmings R, Masood A, Newsome S, Saxton C, Warwick L, Yateman NA, Zuber E. Degtyarev E, et al. Among authors: buyse m. Future Oncol. 2024;20(22):1601-1615. doi: 10.1080/14796694.2024.2357537. Epub 2024 Jun 18. Future Oncol. 2024. PMID: 38889345 Free PMC article.
Reply to J.A. Garcia et al.
Halabi S, Guo S, Roy A, Rydzewska LE, Godolphin P, Hussain M, Tangen C, Thompson I, Xie W, Carducci MA, Morris MJ, Smith MR, Gravis G, Dearnaley DP, Verhagen PJ, Goto TJ, James ND, Buyse ME, Tierney JF, Sweeney CJ. Halabi S, et al. Among authors: buyse me. J Clin Oncol. 2024 Aug 20;42(24):2940-2941. doi: 10.1200/JCO.24.00625. Epub 2024 Jun 14. J Clin Oncol. 2024. PMID: 38875510 No abstract available.
Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials.
Ravi P, Xie W, Buyse M, Halabi S, Kantoff PW, Sartor O, Attard G, Clarke N, D'Amico A, Dignam J, James N, Fizazi K, Gillessen S, Parulekar W, Sandler H, Spratt DE, Sydes MR, Tombal B, Williams S, Sweeney CJ. Ravi P, et al. Among authors: buyse m. Eur Urol. 2024 May 21:S0302-2838(24)02380-7. doi: 10.1016/j.eururo.2024.04.038. Online ahead of print. Eur Urol. 2024. PMID: 38777647
Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer.
Brookman-May SD, Buyse M, Freedland SJ, Miladinovic B, Zhang K, Fendler WP, Feng F, Sartor O, Sweeney CJ. Brookman-May SD, et al. Among authors: buyse m. Eur Urol. 2024 Aug;86(2):81-87. doi: 10.1016/j.eururo.2024.04.024. Epub 2024 May 18. Eur Urol. 2024. PMID: 38762392
469 results